Haemonetics Corp insider trading
Every open-market purchase and sale by Haemonetics Corp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Haemonetics Corp’s insiders pay?
From February 18, 2010 to November 12, 2025, 33 insiders reported 30 open-market purchases and 155 sales not made under a pre-set plan in Haemonetics Corp. Twelve months after each purchase was reported, the shares were −8.9% against the S&P 500 on average (median −4.3%), over 29 purchases with a full year of prices; 48% beat the index. After sales, the shares moved −7.5% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 5, 2010 into $19,440 by November 2, 2026, +4.1% a year. It held shares 42% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $38,310 (+8.5% a year), and held throughout $86,628 (+14.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Simon, Christopher | President & CEO | 1 | +3.4% (1) | 100% | 20 | −14.1% (20) | June 15, 2022 |
| Basil Michelle L | EVP and General Counsel | 0 | — | — | 17 | −11.8% (17) | October 26, 2022 |
| Gelbman Ronald G | Director | 0 | — | — | 14 | −2.9% (14) | November 13, 2019 |
| Burke William P. MR. | EVP, Chief Financial Officer | 0 | — | — | 13 | −12.0% (13) | June 16, 2021 |
| Lindop Christopher J | CFO & EVP Business Development | 6 | −4.3% (6) | 50% | 3 | −15.4% (3) | October 28, 2015 |
| Merriman Ronald | Director | 0 | — | — | 9 | +16.4% (9) | May 24, 2017 |
| Foote Susan Bartlett | Director | 0 | — | — | 8 | +17.5% (8) | November 14, 2017 |
| Kroll Mark W | Director | 1 | — | — | 7 | +3.6% (7) | November 12, 2025 |
| Allen Peter M | President, Global Plasma | 6 | −4.3% (6) | 50% | 1 | −1.5% (1) | May 2, 2013 |
| Best Lawrence C | Director | 1 | −4.8% (1) | 0% | 6 | −6.9% (6) | June 13, 2014 |
| Goldstein Dan | VP, Corporate Controller | 0 | — | — | 7 | −12.1% (7) | June 6, 2022 |
| Granadillo Pedro P | Director | 0 | — | — | 7 | +1.3% (7) | November 9, 2018 |
| Scanlan Jacqueline | SVP, Global Human Resources | 0 | — | — | 7 | −36.1% (7) | June 9, 2021 |
| White Jonathan | Chief Science and Technology | 4 | −11.5% (4) | 50% | 3 | −15.8% (3) | October 28, 2015 |
| Gordon Mikael | President, Global Markets | 2 | +12.6% (2) | 100% | 3 | −5.1% (3) | May 7, 2012 |
| Forish Joseph J | VP, Human Resources | 4 | −11.2% (4) | 50% | 0 | — | May 2, 2013 |
| Jesse Sandra | EVP and Chief Legal Officer | 3 | −26.5% (3) | 0% | 1 | −6.5% (1) | October 28, 2015 |
| Lingamneni Anila | EVP, Chief Technology Officer | 0 | — | — | 4 | +8.1% (4) | June 1, 2023 |
| Meelia Richard J | Director | 0 | — | — | 4 | +0.2% (4) | February 5, 2021 |
| Hanlon Susan M | VP Finance | 0 | — | — | 3 | −13.1% (3) | October 28, 2015 |
| Llorens Josep | EVP, Global Manufacturing | 0 | — | — | 3 | −32.7% (3) | May 23, 2022 |
| Bolorforosh Said | EVP, Chief Technology Officer | 0 | — | — | 2 | −41.2% (2) | November 13, 2019 |
| Miller Laurie A. | SVP, Human Resources | 0 | — | — | 2 | +17.4% (2) | September 21, 2022 |
| Nighan Warren Jr | VP WW Q&R Affairs | 0 | — | — | 2 | −15.8% (2) | December 13, 2012 |
| Ryding Neil MR. | EVP, Global Manufacturing | 0 | — | — | 2 | +8.2% (2) | June 8, 2018 |
| Strong Stewart W | President, Global Hospital | 0 | — | — | 2 | +0.4% (2) | June 9, 2023 |
| Abernathy Robert E | Director | 1 | −61.7% (1) | 0% | 0 | — | August 12, 2020 |
| Davies Kent J | President, Global Markets | 0 | — | — | 1 | −28.8% (1) | July 27, 2015 |
| Dockendorff Charles J | Director | 0 | — | — | 1 | −82.4% (1) | February 5, 2021 |
| Kelly Michael P | President, Global Markets | 0 | — | — | 1 | −22.5% (1) | November 13, 2013 |
| Lopez Alicia R | VP, Corporate Affairs | 1 | +1.4% (1) | 100% | 0 | — | May 4, 2010 |
| Mcdaniel Kathleen | EVP Global Human Resources | 0 | — | — | 1 | +0.7% (1) | September 2, 2014 |
| Selman Byron | President, Global Markets | 0 | — | — | 1 | −6.5% (1) | October 28, 2015 |
When several insiders traded Haemonetics Corp
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Haemonetics Corp in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged −0.6% against the index. After 17 selling crowds, −6.1%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| October 31, 2022 | 3 selling | −7.6% | −10.3% | −9.5% |
| May 31, 2022 | 5 selling | +19.5% | +34.8% | +33.0% |
| February 26, 2021 | 3 selling | −66.4% | −71.1% | −71.4% |
| October 30, 2020 | 3 selling | +11.2% | −65.4% | −72.9% |
| May 29, 2020 | 5 selling | −32.8% | −17.3% | −88.8% |
| June 28, 2019 | 4 selling | +1.9% | −14.9% | −32.9% |
| November 30, 2018 | 3 selling | −22.8% | −7.5% | −4.3% |
| May 31, 2018 | 5 selling | +13.3% | +16.4% | +4.6% |
| November 30, 2017 | 4 selling | +20.2% | +58.3% | +79.7% |
| May 31, 2017 | 3 selling | −0.3% | +33.8% | +107.2% |
| October 30, 2015 | 5 selling | +7.2% | −18.7% | −5.5% |
| March 31, 2015 | 5 selling | −8.1% | −17.5% | −23.8% |